Tanvex BioPharma Inc 2024 SR
The report highlights Tanvex BioPharma's progress in 2024, including the U.S. FDA approval of its first biosimilar drug, TX01. The company formally approved a merger with Bora Biologics to enhance its CDMO capabilities. Environmentally, the company adopted the TCFD framework and identified key climate risks and opportunities. Socially, it maintained a diverse workforce with 49% female representation in management and achieved a 100% retention rate for employees returning from parental leave. Governance remained strong with no reported corruption or cybersecurity incidents.
Company: Tanvex BioPharma Inc
Sector: Health Care
Country: Cayman Islands
Year: 2024
Type: SR
Pages: 97
Tanvex BioPharma Inc
Sustainability Report
The report highlights Tanvex BioPharma's progress in 2024, including the U.S. FDA approval of its first biosimilar drug, TX01. The company formally approved a merger with Bora Biologics to enhance its CDMO capabilities. Environmentally, the company adopted the TCFD framework and identified key climate risks and opportunities. Socially, it maintained a diverse workforce with 49% female representation in management and achieved a 100% retention rate for employees returning from parental leave. Governance remained strong with no reported corruption or cybersecurity incidents.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Jan 1, 2024 - Dec 31, 2024
Fiscal Year
2024
Published
Aug 1, 2025
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Energy Consumption
Renewable Energy
Water Consumption
Total Waste
Women on Board
Women in Management
Workplace Fatalities
Employees